Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b...
Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial
About this item
Full title
Author / Creator
Kuboki, Yasutoshi , Fakih, Marwan , Strickler, John , Yaeger, Rona , Masuishi, Toshiki , Kim, Edward J. , Bestvina, Christine M. , Kopetz, Scott , Falchook, Gerald S. , Langer, Corey , Krauss, John , Puri, Sonam , Cardona, Panli , Chan, Emily , Varrieur, Tracy , Mukundan, Lata , Anderson, Abraham , Tran, Qui and Hong, David S.
Publisher
New York: Nature Publishing Group US
Journal title
Language
English
Formats
Publication information
Publisher
New York: Nature Publishing Group US
Subjects
More information
Scope and Contents
Contents
The current third-line (and beyond) treatment options for
RAS
-mutant metastatic colorectal cancer have yielded limited efficacy. At the time of study start, the combination of sotorasib, a KRAS (Kirsten rat sarcoma viral oncogene homolog)-G12C inhibitor, and panitumumab, an epidermal growth factor receptor (EGFR) inhibitor, was hypothesized...
Alternative Titles
Full title
Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2917421794
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2917421794
Other Identifiers
ISSN
1078-8956,1546-170X
E-ISSN
1546-170X
DOI
10.1038/s41591-023-02717-6
